Privacy Policy

Cookies

If you leave a comment on our site you may opt-in to saving your name, email address and website in cookies. These are for your convenience so that you do not have to fill in your details again when you leave another comment. These cookies will last for one year.

If you visit our login page, we will set a temporary cookie to determine if your browser accepts cookies. This cookie contains no personal data and is discarded when you close your browser.

When you log in, we will also set up several cookies to save your login information and your screen display choices. Login cookies last for two days, and screen options cookies last for a year. If you select “Remember Me”, your login will persist for two weeks. If you log out of your account, the login cookies will be removed.

If you edit or publish an article, an additional cookie will be saved in your browser. This cookie includes no personal data and simply indicates the post ID of the article you just edited. It expires after 1 day.

Comments

 When visitors leave comments on the site we collect the data shown in the comments form, and also the visitor’s IP address and browser user agent string to help spam detection.

An anonymized string created from your email address (also called a hash) may be provided to the Gravatar service to see if you are using it. The Gravatar service privacy policy is available here: https://automattic.com/privacy/. After approval of your comment, your profile picture is visible to the public in the context of your comment.

Media

If you upload images to the website, you should avoid uploading images with embedded location data (EXIF GPS) included. Visitors to the website can download and extract any location data from images on the website.

Embedded content from other websites

Articles on this site may include embedded content (e.g. videos, images, articles, etc.). Embedded content from other websites behaves in the exact same way as if the visitor has visited the other website.

These websites may collect data about you, use cookies, embed additional third-party tracking, and monitor your interaction with that embedded content, including tracking your interaction with the embedded content if you have an account and are logged in to that website.

Who we share your data with

If you request a password reset, your IP address will be included in the reset email.

How long we retain your data

If you leave a comment, the comment and its metadata are retained indefinitely. This is so we can recognize and approve any follow-up comments automatically instead of holding them in a moderation queue.

For users that register on our website (if any), we also store the personal information they provide in their user profile. All users can see, edit, or delete their personal information at any time (except they cannot change their username). Website administrators can also see and edit that information.

What rights you have over your data

If you have an account on this site, or have left comments, you can request to receive an exported file of the personal data we hold about you, including any data you have provided to us. You can also request that we erase any personal data we hold about you. This does not include any data we are obliged to keep for administrative, legal, or security purposes.

Where your data is sent

 Visitor comments may be checked through an automated spam detection service.

27. David Sallman
David Sallman

Moffitt Cancer Center, Tampa, Florida, USA

David Sallman, MD, is an Assistant Member in the Department of Malignant Hematology at Moffitt Cancer Center in Tampa, FL. His clinical interests are myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), and myeloproliferative neoplasms. His research interests focus on the development of novel targeted therapeutic strategies for patients with MDS and AML, based on the underlying mutational drivers of each disease. He has authored numerous articles, books, book chapters, and abstracts and serves as reviewer for multiple journals. In 2017, he received the Young Investigator Grant from the MDS Foundation. 

19. Bart Scott
Bart Scott

University of Washington Medical Center, Seattle, Washington, USA

Bart Scott is a medical oncologist at Fred Hutchinson Cancer Research Center in Seattle, Washington. He is Professor of Medicine in the Division of Oncology at the University of Washington Medical Center and Director of Myeloid Malignancies at the Seattle Cancer Center Alliance. He is board certified in internal medicine and medical oncology by the American Board of Internal Medicine. Dr. Scott received his medical degree from the University of Alabama. He then completed his internship and residency at the Johns Hopkins University School of Medicine in Baltimore, Maryland. He completed his fellowship in medical oncology at the University of Washington in Seattle. Dr. Scott has participated in a number of studies involving myelodysplastic syndromes and myeloproliferative disorders. He has published numerous articles in journals such as American Journal of Medicine ,  Leukemia & Lymphoma ,  Blood , and  Journal of Clinical Oncology . He is also a reviewer for  New England Journal of Medicine ,  British Journal of Haematology ,  Journal of the National Comprehensive Cancer Network , and  Haematologica , among others. Dr. Scott has been an invited lecturer on the management and treatment of myelodysplastic syndromes and transplantation for bone marrow failure. He is a member of the American Medical Association, the American Society of Hematology, the American Society of Clinical Oncology, and the Southwest Oncology Group, among many others.

Pierre_Fenaux
Pierre Fenaux

Hôpital Saint Louis, Paris, France

Pierre Fenaux, is professor of hematology and head of the hematology department at hospitals St Louis, Robert Debré and Avicenne  (belonging to Assistance Publique- Hôpitaux de Paris Hospital network). He is also part of  Inserm research  unit n° 944, at Hôpital St Louis, Paris, for his laboratory research activity  

He is involved in clinical and laboratory research in the field of myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML, mainly AML in the elderly and acute promyelocytic leukemia, APL ). 

He is a founding member and chairman of the French speaking MDS group (Groupe Francophone des Myélodysplasies or GFM) and of the French APL group (GT-LAP).

Immunosuppressive therapy in MDS

Chairperson

Rami Komrokji, MD

Moffitt Cancer Center, Tampa Florida, USA

Faculty

Yazan Migdady

Oregon Health & Science University, Portland, Oregon, USA

Managing isolated neutropenia and thrombocytopenia in Lower risk MDS

Chairperson

Rami Komrokji, MD

Moffitt Cancer Center, Tampa Florida, USA

Faculty

Valeria Santini

University of Florence, Italy

Novel agents for higher risk MDS: be on the look?

Chairperson

Rami Komrokji, MD

Moffitt Cancer Center, Tampa Florida, USA

Faculty

David Sallman

Moffitt Cancer Center, Tampa, Florida, USA

Allogeneic stem cell transplant: how can we cure more patients?

Chairperson

Rami Komrokji, MD

Moffitt Cancer Center, Tampa Florida, USA

Faculty

Bart Scott

University of Washington Medical Center, Seattle, Washington, USA

Luspatercept: where to fit the new kid on the block?

Chairperson

Rami Komrokji, MD

Moffitt Cancer Center, Tampa Florida, USA

Faculty

Pierre Fenaux

Hospital Saint Louis, Paris, France